MDS highlights from ASH 2024

Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, discusses his key myelodysplastic syndrome (MDS) highlights from this year's ASH meeting. Dr Zeidan highlights the progress in lower-risk MDS, particularly with the continued benefit of luspatercept, which has been shown to achieve transfusion independence in approximately 20-30% of patients. Additionally, he notes the interest in adding luspatercept as a backbone strategy to erythropoietin-stimulating agents (ESA) and the promising results of trials investigating hypomethylating agents in higher-risk MDS. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.